These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27785685)

  • 1. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.
    Tsukiyama I; Ejiri M; Yamamoto Y; Nakao H; Yoneda M; Matsuura K; Arakawa I; Saito H; Inoue T
    J Gastrointest Cancer; 2017 Dec; 48(4):326-332. PubMed ID: 27785685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer.
    Kashiwa M; Maeda H
    J Gastrointest Cancer; 2024 Dec; 55(4):1569-1580. PubMed ID: 39172318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
    Roth JA; Carlson JJ
    J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.
    Kashiwa M; Matsushita R
    Int J Clin Pharm; 2023 Aug; 45(4):875-883. PubMed ID: 37079225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
    Phippen NT; Leath CA; Chino JP; Jewell EL; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2012 Nov; 127(2):267-72. PubMed ID: 22892361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
    Chisaki Y; Nakamura N; Yano Y
    Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.
    Xiang G; Huang Y; Gan L; Wang L; Ding Y; Wu Y; Xing H; Liu Y
    Front Immunol; 2024; 15():1426024. PubMed ID: 39346914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
    Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine for the treatment of metastatic breast cancer.
    Jones J; Takeda A; Tan SC; Cooper K; Loveman E; Clegg A
    Health Technol Assess; 2009 Sep; 13 Suppl 2():1-7. PubMed ID: 19804683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
    Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
    Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
    Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A
    Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
    Borget I; Pérol M; Pérol D; Lavolé A; Greillier L; Dô P; Westeel V; Crequit J; Léna H; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Chabaud S; Vergnenegre A; Zalcman G; Chouaïd C;
    BMC Cancer; 2014 Dec; 14():953. PubMed ID: 25511923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.